2013-11-13T03:22:27-00:00 2012-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2012-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 981012795 Homer W Lane Jr 2013-11-08 true Sue Robison 2069134000 2012 2016-02-24 21:20:13Z Gerald Nepom MD PhD 1201 Ninth Avenue Seattle WA 98101 43591930 false X http://www.benaroyaresearch.org X 1956 WA To conduct and encourage high quality medical, surgical, and scientific research and research training in disease and problems of medical importance. 22 17 304 17 0 34328409 38329362 2391006 4701834 10695 10130 612301 349689 37342411 43391015 4194908 4202339 0 20801358 22311686 0 0 13165395 17131610 38161661 43645635 -819250 -254620 69664646 75528821 35554255 40430952 34110391 35097869 X See Schedule O false false 35079287 4202339 4701834 BRI is an international leader in immune system and autoimmune disease research including Type 1 diabetes, arthritis, lupus, multiple sclerosis, and scleroderma. Additional information is provided in Schedule O. 35079287 true true false true false false false false false true false false true false false true false false false true true false false false false false true false true true false false true false false false false false false false false false false false false true false false false false true 47 0 true 304 true false false false false false false false false false false X 22 17 false false false false true true true true true false false true true true true true true true true false WA X Homer W Lane Jr Executive DirectorC 2063426508 1201 Ninth Avenue Seattle WA 981012795 Carla Greenbaum MD 040.00 X 205255 0 30903 Gerald Nepom MD PhD 040.00 X 471408 0 41336 Joyce Lammert MD PhD 001.00 050.00 X 0 564202 48492 John Corman MD 001.00 050.00 X 0 500585 69457 Gary Kaplan MD 001.00 054.00 X 0 1507637 2230041 Tom Cohen 001.00 X 0 0 0 Rebecca Campbell 001.00 X 0 0 0 Kristi Pangrazio 001.00 004.00 X X 0 0 0 Margaret Morrow 001.00 X X 0 0 0 Miriam Sevy 001.00 X X 0 0 0 Frank Dvorak PhD 001.00 X 0 0 0 Trish Markey 001.00 X 0 0 0 Stuart Klorfine 001.00 X 0 0 0 Edward Drosdick 001.00 X 0 0 0 Thomas Kelly 001.00 X 0 0 0 Ditman Johnson 001.00 X 0 0 0 Gaylia Meitzen 001.00 X 0 0 0 Michael Gallatin 001.00 X 0 0 0 Jessica Muffett 001.00 X 0 0 0 Carla DewBerry 001.00 X X 0 0 0 Ann Sobil 001.00 X 0 0 0 Christopher Wilson MD 001.00 X 0 0 0 Homer Lane Jr 040.00 X 209238 0 17912 Jack Nagan 040.00 X 295162 0 29496 Jane Buckner MD 040.00 X 210116 0 25056 William Kwok PhD 040.00 X 202591 0 26352 Jason Wood 040.00 X 168902 0 13639 Thomas Wight PhD 040.00 X 176017 0 37376 Steven Ziegler PhD 040.00 X 183162 0 19651 2121851 2572424 2589711 33 false true false Davis Wright Tremaine LLP 1201 Third Ave Ste 2200 Seattle WA 98101 Consulting 160836 DNA Brand Mechanics 1301 Fifth Ave Suite 2600 Seattle WA 98101 Consulting 136491 KPMG LLP 1918 Eighth Ave Suite 2900 Seattle WA 98101 Auditing Consulting 111175 3 4843000 25250569 8235793 38329362 Sponsored research 621500 3113096 3113096 Core services 621500 1588738 1588738 4701834 10130 10130 550604 200915 349689 349689 348689 43391015 4701834 358819 3994654 3994654 0 207685 207685 0 2121071 1357288 763783 0 15190630 11840644 3349986 1232381 910782 321599 2640144 1951179 688965 1127460 833241 294219 0 32454 32454 83675 83675 0 0 1416385 818301 598084 186521 186521 192197 27749 164448 514670 116001 398669 0 2199825 1946322 253503 297916 253584 44332 0 66563 54434 12129 918270 804680 113590 0 2528926 2003391 525535 50342 50342 Supplies 4171778 3918362 253416 Other Purchased Services 174446 141603 32843 Patient Costs 914920 914920 Research Participants Fee 163197 163197 3219525 2821270 398255 43645635 35079287 8566348 0 14965749 15153492 7298328 8012726 385563 772245 225459 236122 62600670 29223226 31125599 33377444 15663948 17976792 69664646 75528821 7758745 6777563 1679839 3106899 25100671 10390000 1015000 20156490 35554255 40430952 X 21811264 21449630 3812326 4736875 8486801 8911364 34110391 35097869 69664646 75528821 -254620 1242098 X false true X true true true X Virginia Mason Medical Center Seattle WA 0.00000 0.00000 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 127874 6000 133874 43645635 984166097 43645635 984299971 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 269422 270061 222311 133874 895668 250001 250000 250000 250000 1000001 1500002 152146 151772 122311 127874 554103 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Election Member. Grassroots Lobbying Expenditures 127,874. Direct Lobbying Expenditures 6,000. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2012. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. false 756906 756906 45637796 17500699 28137097 196862 196862 14582369 11525665 3056704 1426737 1426737 33377444 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 16667603 Fringe benefit receivable 729871 Deferred financing costs, net 534956 Due from affiliates, net 44362 17976792 Federal income taxes 44633113 1242098 1242098 43391015 43391015 43645635 43645635 43645635 true North America Conferences Medical Research 1610 East Asia and the Pacific Conferences Medical Research 3707 Europe Conferences Medical Research 18122 Central America and the Caribbean Conferences Medical Research 2641 26080 26080 North America Medical Research 95290 Wire Transfer East Asia and the Pacific Medical Research 94013 Wire Transfer Europe Medical Research 24390 Wire Transfer 3 false false false false false false I 2 Subrecipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing Federal Grants. The policy provides assurance that subrecipients comply with Federal Grant requirements. This policy requires subrecipients to provide annual audited reports that identify compliance with laws and regulations and have met the requirements of OMB Circular A-133. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations which includes the annual A-133 audit. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. I 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. II 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Blood Systems Research 270 Masonic Ave San Francisco CA 94114 860098929 501c3 17668 Medical Research California Institute of Technology 1200 E California Blvd Pasadena CA 91125 951643307 501c3 140522 Medical Research Duke University Subcontractor Inst AR Charlotte NC 28260 560532129 501c3 121735 Medical Research La Jolla Inst for Allergy & Immun 9420 Athena Circle La Jolla CA 92037 330328688 501c3 49970 Medical Research Lab Key Software 2226 Eastlake Ave E Seattle WA 98102 208266728 959581 Medical Research Oregon HSU 0690 SW Bancroft St Portland OR 97239 931176109 Oregon 70572 Medical Research Rockefeller University 1230 York Ave Box 259 New York NY 10021 131624158 501c3 18841 Medical Research Seattle Biomedical Res Inst 307 Westlake Ave N Ste 500 Seattle WA 98072 910961784 501c3 143933 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 98124 910564748 501c3 465841 Medical Research The Res Inst at Nationwide 700 Childrens Drive Columbus OH 43271 316056230 501c3 153744 Medical Research UC Regents Univ of California 9500 Gilman Drive La Jolla CA 92093 956006144 California 45008 Medical Research University of Colorado PO Box 910238 Denver CO 80291 846000555 501c3 97476 Medical Research Univ of Florida Board of Trustee PO Box 113001 Gainsville FL 32611 596002052 501c3 60104 Medical Research Univ of Kentucky Res Fndn 301 Peterson Svc Bldg Lexington KY 40506 616033693 501c3 12373 Medical Research University of Pennsylvania PO Box 785541 Philadelphia PA 19178 231352685 Pennsylvania 157794 Medical Research University of Rochester 910 Genesee St Ste 200 Rochester NY 14611 160743209 New York 14159 Medical Research University of Virginia PO Box 400195 Charlottesville VA 22904 546001796 Virginia 34856 Medical Research University of WA Grants 12455 Collections Dr Chicago IL 60693 916001537 Washington 1418869 Medical Research Yale University PO Box 1873 New Haven CT 06508 080648973 501c3 20390 Medical Research 18 1 I 2 Subrecipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing Federal Grants. The policy provides assurance that subrecipients comply with Federal Grants requirements. This policy requires subrecipients to provide annual audited reports that identify compliance with laws and regulations and have met the requirements of OMB Circular A-133. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations which includes the annual A-133 audit. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. false true false false false false false false false Carla Greenbaum MD 205255 22500 8403 236158 Gerald Nepom MD PhD 367442 103966 39500 1836 512744 Joyce Lammert MD PhD 422477 123436 18288 34638 13854 612693 John Corman MD 500214 100 270 45849 23608 570041 Gary Kaplan MD 1039978 449871 17788 2199932 30109 3737678 Homer Lane Jr 208911 327 10462 7450 227150 Jack Nagan 216911 78251 26000 3496 324658 Jane Buckner MD 210116 22500 2556 235172 William Kwok PhD 202031 560 22500 3852 228943 Jason Wood 168902 13639 182541 Thomas Wight PhD 175457 560 22500 14876 213393 Steven Ziegler PhD 182602 560 13675 5976 202813 I 3 Benaroya Research Institute at Virginia Mason relies upon Virginia Mason Medical Centers a related organization Board Compensation and Benefits Committee, a committee composed of independent board members to whom the Board has delegated the authority to approve all compensation and benefits for the executive leaders of the Medical Center. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data, from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. I 4b The Medical Center has a Supplemental Executive Retirement Plan SERP. The SERP is a 457f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into when certain senior executives join the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits for the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. A WA Econ Devel Fin Auth-2012 Series B 911493002 2012-06-01 10390000 See Part VI false true false A 10390348 2550348 true false true true A false true false true true 0.00800 0.00800 true false false A false true false false false false false A false I A f Purposes to currently refund WEDFA Series 2006C bonds issued 11/15/2006, and to fund research facility improvements. II 3 Difference between Part I, column e and Part II, Line 3 is investment earnings. Form 990 Part III Line 1 Benaroya Research Institute at Virginia Mason BRI is a world-renowned medical research institute whose work has resulted in major advances against 80 autoimmune diseases. One in 20 Americans suffers from one or more autoimmune diseases, such as type 1 diabetes, multiple sclerosis, Crohns disease and rheumatoid arthritis to name a few. Because all autoimmune diseases are connected in the way the immune system attacks the body, BRI scientists arent focused on eliminating one or two autoimmune diseases - they are taking on many more. As a world leader in scientific innovation, BRIs discoveries are having significant impact on people living with autoimmune diseases today - by improving the ability to predict disease risk, decreasing disease progression and making therapies safer and better. Form 990 Part III Line 4a One of the unique qualities of BRI is the close integration of three types of medical research - laboratory research, translational research and clinical research - to improve peoples lives. Our scientists can address both the basic science issues and clinical applications, which is the best way to design studies with the highest potential for success. For BRI, discovery starts in the laboratory. A Laboratory advances in 2012 include 1 A breakthrough discovery of how allergy shots steer the immune response to prevent allergies. These findings open new horizons for understanding allergic disease and improving safety and efficacy of current allergy shots. 2 Decoding how a common change in a gene called PTPN22 may predispose children and adults to develop autoimmune diseases including Type 1 diabetes, rheumatoid arthritis and lupus. A team of researchers from BRI and Seattle Childrens are now testing how this gene may help predict the people who are at risk for autoimmune conditions and whether a therapy can be developed to compensate for this genetic change. 3 Finding a new complexity in the immune system - a mirror regulatory cell for each kind of helper T cell to tell it how to respond. 4 Discovery of a molecular pathway to regulate macrophages - cells in the immune system that are some of the first responders at sites of injury, infection and inflammation. B Translational research is the link between laboratory research and clinical research, built upon an exchange of materials and information between these two disciplines. BRI scientists and collaborators work together to study blood and serum samples along with medical and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy and asthma. BRI maintains an extensive biorepository with samples dating back to 2000, including 11 disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2012 include the following 1 BRI established a new translational research core laboratory called the Human Immunophenotyping Core. Scientists use this core to identify the underlying mechanisms of disease and develop biomarkers of disease. The core is also a designated laboratory for the Immune Tolerance Network ITN. BRI Director Gerald T. Nepom, MD, PhD, serves as the director of the ITN, one of the largest government-funded clinical research networks in the nation working to accelerate new treatments for diseases of the immune system. 2 The BRI Diabetes Research Program received a 4.4 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to establish the T1D Exchange Biobank Operations Center. 3 BRI scientists began new partnerships with several biopharmaceutical companies to potentially speed up translational research of diagnosis and treatment of autoimmune and immune-mediated diseases. C Clinical research studies are conducted with volunteers who participate in experimental medical approaches not available outside the clinical trial setting, and play a major role in pushing the boundaries of knowledge about their disease and new therapies. BRI conducts nearly 100 trials each year in many different diseases through a Diabetes Research Program partnership with Seattle Childrens , TrialNet and the National Institutes of Health trials with the Immune Tolerance Network and the BRI Clinical Research Program with physicians at Virginia Mason. Advancements in 2012 include 1 Multiple sclerosis research. Participation in clinical trials led to the FDA approval of a second oral agent teriflunomide for multiple sclerosis and a third anticpated in 2013. Studies in 2013 will focus on the possibility of remyelination as well as impact of treatment on brain volume measurements. Translational work also remains active with exploration of biomarkers to guide treatment decisions. 2 Rheumatology research. BRI was part of the pivotal trials for the first drug in a new class of immunotherapies called JAK inhibitors. This is the first oral medication to be approved in a number of years and the only major drug approved for rheumatoid arthritis in 2012. 3 Type 1 diabetes research. Clinical trials included the study of an artifical pancreas, new experimental drugs to modify the immune response, whether vitamin D can change how immune cells function, better ways to measure insulin secretion and how best to monitor patients at risk of developing type 1 diabetes. D Prevention is the ultimate goal of early diagnosis, before autoimmune diseases become a clinical problem. One of the important lessons learned in BRIs quest to diagnose, better treat and cure autoimmune diseases is that the earlier intervention, the better. Several pioneering advancements at BRI in 2012 focused on prevention 1 Calculating an individualss risk for the development of type 1 diabetes through the publication of a practical algorithm by BRI and collaborators at TrialNet. With this discovery, at-risk people can be closely monitoried and have opportunities to enter a prevention trial. 2 Exploring how to interrupt the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the pre-diabetic state and thereby prevent or delay the onset of type 1 diabetes. BRI is participating in an experimental drug therapy prevention trial sponsored by TrialNet offered to relatives of people with diabetes who are themselves at very high risk for developing the disease. 3 Researching how to restore balance between good and harmful cells involved in initiating disease, by regulating the immune response. BRI will lead a 2.6 million study to understand how the immune system becomes unbalanced and how it might be manipulated in people with autoimmune diseases. 4 Looking for the genetic roots of type 1 diabetes. three different research strategies are being used together to follow the precise molecular steps that are caused by susceptibility genes associated with type 1 diabetes, in a new 4.3 million grant to BRI investigators. 5 Identifying key infectious triggers and regulators of a molecule called TSLP, a key component of the early immune response in the lung airways leading to asthma and allergies. E Immunology research is driving toward individualized treatment for each person with autoimmune and immune-mediated diseases. Each persons genetics, environment and immune system mechanisms are unique, and people react to therapies differently and their responses may change over time. The optimal approach will be to individualize health care for each person and offer the right treatment at the right time. BRI is leading several worldwide efforts to personalize medicine 1 Developing a way to provide an immune system profile for individual patients. The profile will detail the expression of thousands of genes over a persons lifetime. The goal is to provide an early warning of things to come and an indication of what treatments might be needed. In 2012, the development of a low-cost genomic fingerprinting assay enabled BRI researchers to generate immune signatures of hundreds of patients with infectious and autoimmune diseases. Such an assay may on day make its way to the clinic where tools for evaluating immune health are critically needed. 2 Development of new biomarkers to allow individualized studies of responses to vaccines and food allergies.k Biomarkers were also developed to study individuals with the highest level of risk for developing type 1 diabetes. BRI serves as the inventor and international leader for the production and application of biomarkers that have contributed to a broad array of scientific advances, including the study of individual immune responses to better understand disease and how to personlize treatment. Form 990 Part VI Section A Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors. The Director and the Executive Director of the corporation serve as ex officio members of the Executive Committee, without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or removed any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990 Part VI Section A Line 6, 7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights 1 Election or appointment of Directors and Officers of the Board of Directors 2 Removal of Directors and Officers of the Board of Directors including any executive officer of the corporation 3 Approval of all long-range and short-range plans proposed by the Board of Directors 4 Approval of the annual capital and operating budgets proposed by the Board of Directors 5 Approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 6 Approval of the salel, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets 7 Approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation 8 All other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990 Part VI Section B Line 11B Review of the Form 990 Process. The Virginia Mason Health System Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including 1 selection, engagement, and review of the performance of the independent tax preparer, 2 review of the annual draft Form 990 tax return, and 3 recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provides the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final draft Form 990 is reviewed and approved by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. Form 990 Part VI Section B Line 12C The Virginia Mason Health System Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the Benaroya Research Institute at Virginia Mason Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has 1 received a copy of the Conflict of Interest Policy 2 has read and understands the Policy 3 has agreed to comply with the Policy and 4 understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaires be completed annually by each Covered Person and any Conflict of Interest Management Plan be maintained. Form 990 Part VI Section B Line 15 The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with VMHS/BRIs philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committees assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with VMHS/BRIs compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individuals who were reviewed in 2012 were the Board Director, Carla Greenbaum, the Executive Director and Chief Financial Officer, and Vice President and Research Executive Director. Form 990 Part VI Section C Line 19 The organizations Articles, Bylaws, Conflicts of Interest Policy and financial statements are made available upon request. Virginia Mason Health System (VMHS) 1100 Ninth Ave Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7-Support General Pu N/A true Virginia Mason Medical Center 1100 Ninth Ave Seattle WA 98101 910565539 Health Care WA Sec 501c3 3-Hospital VMHS false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 98101 910653422 0 0 0 43645635 43645635 44342 11086 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 X 127874 6000 133874 924077890 924211764 938953 234738 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 13866752 13866752 14088 3522 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 0 0 0 2575820 2575820 2617 654 0 0 0